The developments for bladder carcinoma are moving fast. That is why you can watch LIVE on Tuesday the 29th of November between 8:00 and 9:30 pm at the e-learning‚ Bladder carcinoma update 2022‘ (can also be viewed on demand). The basis for this accredited program is formed by the news of, among others, ASCO GU, ASCO, ESMO and ASTRO.

Under the leadership of prof. Fred Witjes, a fine panel of experts from The Netherlands and Belgium discuss the most important news for both the early stage setting and the metastatic setting, whereby a translation is made into clinical practice.

Subject early stage setting

• Bladder-sparing combination treatments
  • Radiotherapy + chemotherapy
  • Radiotherapy + immunotherapy
• Neoadjuvant and adjuvant treatments, including
  • Adjuvant chemotherapy
  • Adjuvant immunotherapy
  • Neoadjuvant immunotherapy/chemotherapy

Subject developments  with ADC’s

Subject metastatic  setting

• Developments with immunotherapy/updates PD(L)1-inhibitors

Target audience
The program is primarily aimed at oncologists and urologists, but is also interesting for pathologists, surgeons, radiotherapists and nurse specialists.